NATCO Pharma Limited

NSEI:NATCOPHARM Stock Report

Market Cap: ₹246.2b

NATCO Pharma Valuation

Is NATCOPHARM undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of NATCOPHARM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: NATCOPHARM (₹1374.75) is trading above our estimate of fair value (₹1006.05)

Significantly Below Fair Value: NATCOPHARM is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NATCOPHARM?

Key metric: As NATCOPHARM is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for NATCOPHARM. This is calculated by dividing NATCOPHARM's market cap by their current earnings.
What is NATCOPHARM's PE Ratio?
PE Ratio12.7x
Earnings₹19.45b
Market Cap₹246.23b

Price to Earnings Ratio vs Peers

How does NATCOPHARM's PE Ratio compare to its peers?

The above table shows the PE ratio for NATCOPHARM vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average51.9x
506943 J. B. Chemicals & Pharmaceuticals
43.6x19.4%₹266.4b
524558 Neuland Laboratories
67.9x33.9%₹189.8b
ERIS Eris Lifesciences
53.4x30.7%₹186.0b
GLAND Gland Pharma
42.6x25.8%₹294.4b
NATCOPHARM NATCO Pharma
12.7x-20.4%₹246.2b

Price-To-Earnings vs Peers: NATCOPHARM is good value based on its Price-To-Earnings Ratio (12.7x) compared to the peer average (51.9x).

Price to Earnings Ratio vs Industry

How does NATCOPHARM's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
INDSWFTLAB Ind-Swift Laboratories
1.6xn/aUS$71.82m
524652 Ind-Swift
2xn/aUS$13.29m
No more companies available in this PE range
NATCOPHARM 12.7xIndustry Avg. 32.2xNo. of Companies19PE020406080100+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: NATCOPHARM is good value based on its Price-To-Earnings Ratio (12.7x) compared to the Indian Pharmaceuticals industry average (32.2x).

Price to Earnings Ratio vs Fair Ratio

What is NATCOPHARM's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NATCOPHARM PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio12.7x
Fair PE Ratio22x

Price-To-Earnings vs Fair Ratio: NATCOPHARM is good value based on its Price-To-Earnings Ratio (12.7x) compared to the estimated Fair Price-To-Earnings Ratio (22x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst NATCOPHARM forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₹1,374.75
₹1,343.09
-2.3%
23.9%₹1,675.00₹690.00n/a11
Nov ’25₹1,426.90
₹1,348.73
-5.5%
24.0%₹1,675.00₹690.00n/a11
Oct ’25₹1,400.30
₹1,283.27
-8.4%
24.0%₹1,625.00₹690.00n/a11
Sep ’25₹1,537.55
₹1,249.25
-18.8%
25.3%₹1,625.00₹690.00n/a12
Aug ’25₹1,362.00
₹1,063.75
-21.9%
18.7%₹1,250.00₹620.00n/a12
Jul ’25₹1,198.95
₹1,063.75
-11.3%
18.7%₹1,250.00₹620.00n/a12
Jun ’25₹997.65
₹1,063.75
+6.6%
18.7%₹1,250.00₹620.00n/a12
May ’25₹1,018.15
₹975.36
-4.2%
18.2%₹1,200.00₹620.00n/a11
Apr ’25₹973.70
₹930.82
-4.4%
19.0%₹1,125.00₹620.00n/a11
Mar ’25₹982.75
₹912.30
-7.2%
19.2%₹1,125.00₹620.00n/a10
Feb ’25₹869.30
₹822.45
-5.4%
18.8%₹1,125.00₹515.00n/a11
Jan ’25₹818.35
₹823.73
+0.7%
18.6%₹1,125.00₹515.00n/a11
Dec ’24₹785.40
₹812.25
+3.4%
18.7%₹1,125.00₹515.00n/a12
Nov ’24₹741.55
₹831.67
+12.2%
20.6%₹1,125.00₹480.00₹1,426.9012
Oct ’24₹873.05
₹809.17
-7.3%
21.9%₹1,125.00₹480.00₹1,400.3012
Sep ’24₹902.60
₹790.38
-12.4%
23.0%₹1,125.00₹480.00₹1,537.5513
Aug ’24₹824.75
₹670.08
-18.8%
15.6%₹900.00₹480.00₹1,362.0013
Jul ’24₹693.20
₹658.54
-5.0%
12.9%₹750.00₹480.00₹1,198.9513
Jun ’24₹622.95
₹658.54
+5.7%
12.9%₹750.00₹480.00₹997.6513
May ’24₹574.95
₹643.77
+12.0%
15.4%₹816.00₹450.00₹1,018.1513
Apr ’24₹563.35
₹640.69
+13.7%
15.7%₹816.00₹450.00₹973.7013
Mar ’24₹538.70
₹640.69
+18.9%
15.7%₹816.00₹450.00₹982.7513
Feb ’24₹529.20
₹679.92
+28.5%
12.4%₹816.00₹460.00₹869.3012
Jan ’24₹561.65
₹679.92
+21.1%
12.4%₹816.00₹460.00₹818.3512
Dec ’23₹576.95
₹709.08
+22.9%
19.0%₹1,060.00₹460.00₹785.4012
Nov ’23₹622.85
₹779.69
+25.2%
16.6%₹1,060.00₹515.00₹741.5513

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

Bal Pharma

₹2.2b

Manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally.

BALPHARMA

₹134.50

7D

11.6%

1Y

27.4%

Mercury Laboratories

₹1.1b

Develops, manufactures, markets, distributes, and sells pharmaceutical drugs, medicines, and formulations for mother and child healthcare in India and internationally.

538964

₹911.45

7D

-3.5%

1Y

18.7%

Caplin Point Laboratories

₹147.7b

Engages in the development, production, marketing, and export of generic pharmaceutical formulations and branded products in India.

CAPLIPOINT

₹1,942.80

7D

-0.4%

1Y

58.1%